|
Ocular
Microbiology and Immunology Group
Back
to OMIG Main Page
Previous | 2024 Agenda and Abstracts | Next
2024 OMIG Abstract
Harnessing the Power of Macrophage Secretome to Combat Corneal Scarring Following Microbial Keratitis
Gink Yang1,2, Andrew Wang1,2, Manisha Shah1,2, and Mark Daniell1,2
1Centre for Eye Research Australia (CERA), East Melbourne, Victoria, Australia; 2Department of Surgery (Ophthalmology), Medicine Dentistry and Health Science, University of Melbourne, Melbourne, Victoria, Australia
Purpose: Microbial keratitis is a leading cause of blindness worldwide, characterized by painful ulceration and scarring of the cornea. Delays in diagnosis and rise in antibiotic resistance have reduced the effectiveness of antibiotics, leaving the cornea at risk of prolonged tissue damage. Given that the fibrotic process is mediated by multiple factors, previous studies targeting a single pro-fibrotic mediator such as using TGF-β1 blocker failed to reduce scarring. Resident corneal macrophages (Mφ) are known to secrete factors that regulate inflammation and maintain transparency of the cornea, thereby regulating tissue repair and fibrosis. Collectively named as the macrophage secretome (MφS), we aim to investigate whether treatment using MφS could reduce fibrosis during corneal scarring.
Methods: In our in vitro study, MφS collected from THP1-derived macrophages was used to treat fibrotic primary keratocytes in culture. The expression of fibrosis and corneal clarity related genes in the keratocytes were analyzed using RT-qPCR. Conversely, secretome collected from keratocytes-derived myofibroblasts was used to treat THP1 monocytes. The level of key immune regulators in the monocytes was analyzed using ELISA.
Results: MφS released by monocyte-derived macrophages activated at various levels had differential effect on fibrosis suppression, while maintaining stromal integrity necessary for corneal clarity.
Conclusions: Targeting fibrosis using MφS at different stages has the potential to suppress scarring in the cornea.
Disclosure: S
Support: Early and Mid-Career Researcher Grant from the University of Melbourne and CERA’s Innovation Fund (GY)
Previous | 2024 Agenda and Abstracts | Next
|
|